Loading stock data…
ALDX
$1.76+0.03 (+1.73%)
Market ClosedLast close May 11
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aldeyra Therapeutics, Inc. in the Healthcare sector is trading at $1.76. The stock is currently near its 52-week low of $1.07, remaining 60.6% below its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why ALDX maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.76
Potential Upside
5%
Whystock Fair Value$1.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$9.00+411.4%
Range$4.00 – $13.00
Fundamentals
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$96.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-76.49%
Volume
Today's trading volume
712,629
Recent News
Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value
In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.
Discover 3 Stocks That Might Be Trading Below Estimated Value
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%
The United States market has remained flat over the last week but has seen a significant rise of 29% over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential growth while navigating current market conditions.
3 Stocks That May Be Trading Below Their Estimated Value In April 2026
Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has risen by an impressive 29%, with earnings forecasted to grow by 16% annually. In these conditions, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.